世卫组织暂停了羟氯喹的研究

The World Health Organization is pausing the use of hydroxychloroquine in its global study of COVID-19 treatments amid a review of safety data, officials announced Monday.
周一，世界卫生组织官员宣布，审查安全数据期间，在对新冠病毒疗法的全球研究中暂停使用羟氯喹。
The move follows findings from a large observational study, published Friday, that found increased risk of heart problems and death in COVID-19 patients who used chloroquine and hydroxychloroquine.
此前，在周五发表的一项大型观察性研究中发现，使用氯喹和羟氯喹的新冠病人患心脏病和死亡的风险会增加，因此做出这一决定。
It’s a scientific decision nonetheless fraught with politics: U.S. President Donald Trump is a champion of hydroxychloroquine, revealing last week that he’s taking it to prevent COVID-19. He has threatened to cut off U.S. funding to the WHO within a month absent unspecified reforms.
尽管如此，但这一科学决定充满政治因素：美国总统唐纳德·特朗普支持羟氯喹，他上周说正在吃羟氯喹来预防感染新冠病毒。他威胁说，如果不进行具体改革，将在一个月内切断美国对世界卫生组织的资金支持。
The executive committee of the WHO’s Solidarity trial met last Saturday, said WHO Chief Scientist Soumya Swaminathan, and decided “in the light of this uncertainty that we should be proactive, err on the side of caution and suspend enrollment temporarily into the hydroxychloroquine arm.” (Chloroquine is not part of the trial.)
世界卫生组织首席科学家Soumya Swaminathan说，世界卫生组织的SOLIDARITY临床试验执行委员会上周召开会议，决定“鉴于这种不确定性，我们要有前瞻性，谨慎行事，暂停使用羟氯喹”。（氯喹并不是此次试验用药。）
The meeting came a day after the Lancet published the largest observational study of the malaria drugs to date, and as some national regulators began expressing concern about using the drug.
会议召开前一天，《柳叶刀》发表了迄今针对疟疾药物最大的观察性研究，一些国家监管机构开始表现出对使用这种药物的担忧。
WHO officials estimated the pause would last a week or two as the trial’s data safety monitoring board considers information already collected from the Solidarity trial and other ongoing studies to determine whether it’s safe to continue with hydroxychloroquine.
世界卫生组织官员估计暂停会持续一至两周，因为试验数据安全监测委员会要参考从SOLIDARITY临床试验和其他进行中的研究中所收集的信息，从而确定继续使用羟氯喹是否安全。
The study, a randomized trial, has enrolled 3,500 patients in at least 17 countries since March to study four medicines, including hydroxychloroquine.
这项研究是随机试验，从三月份开始在至少17个国家召集了3,500名患者来研究4种药物，其中就包括羟氯喹。